gdc
Side-Effects Management

Drugs for Side-Effects Management (Supportive Care)

Here are the financial support services available to patients receiving treatment for Side-Effects Management (Supportive Care).

2018 Patient Guide to Cancer Support Services
Anemia

Aranesp (darbepoetin alfa)

Drug company: Amgen
888-427-7478

Aranesp is an erythropoiesis-stimulating drug used for the treatment of patients with anemia associated with myelosuppressive chemotherapy.

Amgen offers 1 financial assistance program for patients using Aranesp:

Amgen Safety Net Foundation

Patients with limited or no drug coverage, and patients with Medicare Part D who satisfy the income eligibility requirements, can receive Aranesp for free through this nonprofit program from Amgen.

Epogen (epoetin alfa)

Drug company: Amgen
888-427-7478

Epogen is an erythropoiesis-stimulating drug used for the treatment of patients with anemia associated with myelosuppressive chemotherapy.

(Amgen currently does not offer any financial assistance programs for Epogen.)

Injectafer (ferric carboxymaltose injection)

Drug company: American Regent
877-448-4766

Injectafer is an iron replacement drug used for the treatment of adult patients with anemia associated with iron deficiency in patients with cancer.

American Regent offers 2 financial assistance programs for patients using Injectafer:

Injectafer Savings Program

Qualified patients with private insurance, or those who are paying cash, will pay as little as $50 for the first dose of up to 750 mg of iron and as little as $0 for the second dose of up to 750 mg of iron, with a maximum savings of $500 per dose, and a $1,000 program limit for coverage up to 2 doses.

Injectafer Patient Assistance Program

Uninsured patients who meet certain financial criteria may be eligible to receive Injectafer free of charge.

Bone Metastases/Reduced Bone Mass

Prolia (denosumab) Injection

Drug company: Amgen
888-427-7478

Prolia is a RANK ligand inhibitor used to increase bone mass in adults at high risk for fracture, specifically men who receive androgen-deprivation therapy for nonmetastatic prostate cancer and women who receive adjuvant aromatase inhibitor therapy for breast cancer.

Amgen has 3 financial assistance programs available for patients using Prolia:

Prolia Copay Program

Through this program, eligible patients with private insurance will pay $25 or less out-of-pocket for each dose of Prolia, with an annual benefit of up to $1,500.

Prolia FIRST STEP Program

For privately insured patients whose insurance covers Prolia, this program provides a copay of $0 for the first dose and $25 for each dose thereafter, with a maximum benefit of $1,500 per patient per calendar year.

Amgen Safety Net Foundation

Patients with limited or no drug coverage, and patients with Medicare Part D who satisfy the income eligibility requirements, can receive Prolia for free through this nonprofit program from Amgen.

Xgeva (denosumab)

Drug company: Amgen
888-427-7478

Xgeva is a RANK ligand inhibitor used for the prevention of skeletal-related events in patients with bone metastases from solid tumors, as well as for the treatment of patients with giant-cell tumor of the bone.

Amgen offers 2 financial assistance programs for patients using Xgeva:

Xgeva First Step

For privately insured patients whose insurance covers Xgeva, this program ensures a copay of $0 for the first dose, and then $25 for each dose thereafter, with a maximum benefit of $10,000 per patient per calendar year.

Amgen Safety Net Foundation

Patients with limited or no drug coverage, and patients with Medicare Part D who satisfy the income eligibility requirements, can receive Xgeva for free through this nonprofit program from Amgen.

Cancer Pain

Actiq (fentanyl citrate)

Drug company: Teva
888-587-3263

Actiq is an opioid agonist used for the treatment of breakthrough pain in patients with cancer.

(Teva does not currently offer any direct financial assistance programs for Actiq.)

Fentora (fentanyl buccal tablet)

Drug company: Teva
888-587-3263

Fentora is used for the treatment of breakthrough pain in patients with cancer.

Teva offers 2 financial assistance programs for patients using Fentora:

Fentora Savings Card

Privately insured patients who are enrolled in the TIRF REMS Access Program (www.tirfremsaccess.com) are eligible to use this savings card. With the Fentora Savings Card, the first month of Fentora is free, and subsequent months require a $5 copay.

Teva Cares Foundation Patient Assistance Program

Patients without prescription drug coverage who meet specific financial criteria may receive Fentora for free. The financial criteria specify that the patient’s annual income must not exceed $36,180 for 1 person, $48,720 for 2 people, $61,260 for 3 people, $73,800 for 4 people, or $86,340 for 5 people.

Lazanda (fentanyl)

Drug company: Depomed
877-546-5779

Lazanda is an opioid agonist used for the treatment of breakthrough pain in patients with cancer.

Depomed offers 1 financial assistance program for patients using Lazanda:

Lazanda Savings Card

Privately insured patients are eligible for this prescription savings card. With the card, patients will receive up to 10 free bottles of Lazanda for a $0 copay. The offer is good for up to 5 bottles per fill, and up to 3 refills during the first month of treatment. After the first month, patients will pay a $5 copay for Lazanda, with a maximum benefit of $625. The card may be used at retail or specialty pharmacies.

Subsys (fentanyl sublingual spray)

Drug company: Insys
855-766-6502

Subsys is an opioid agonist used for the treatment of breakthrough pain in patients with cancer.

Insys offers 1 financial assistance program for patients using Subsys:

Subsys Copay Savings Program

Privately insured and uninsured patients can use this copay savings card to receive 10 free units of 100-mcg Subsys and/or up to 30 free units of 200 mcg to 1600 mcg of Subsys. Patients will also receive up to $1,000 off each additional prescription of Subsys.

Chemotherapy-Induced Nausea and Vomiting

Akynzeo (netupitant and palonosetron)

Drug company: Helsinn
844-357-4668

Akynzeo is a fixed combination of netupitant and palonosetron used for the prevention of acute and delayed nausea and vomiting associated with cancer chemotherapy.

Helsinn Cares offers 3 financial assistance programs for patients using Akynzeo:

Akynzeo Pay $0 Savings Program

Privately insured patients will benefit from this program. Privately insured patients will pay $0 copay for each prescription, with an $1,800 annual limit. Patients paying in cash will pay up to $150 per prescription, and up to a maximum of $1,800 annually.

Helsinn Cares Patient Assistance Program

This program provides Akynzeo at no cost to patients with financial needs who meet the program’s eligibility criteria.

Akynzeo Quick Start Voucher Program

This program is for patients whose insurance company requires prior authorization for Akynzeo. To be assessed for eligibility for the Akynzeo Quick Start Voucher Program, patients must be enrolled in Helsinn Cares. The program is available for all eligible patients with commercial or government-sponsored insurance plans. Through the Akynzeo Quick Start Voucher Program, patients will receive 1 free dose of Akynzeo during the insurance verification period.

Aloxi (palonosetron hydrochloride)

Drug company: Eisai/Helsinn
866-613-4724

Aloxi is a serotonin-3 receptor antagonist used to prevent acute and delayed nausea and vomiting associated with cancer chemotherapy in pediatric and adult patients.

Eisai offers 1 financial assistance program for patients using Aloxi:

Aloxi Patient Assistance Program

This program provides Aloxi at no cost to patients with financial needs who meet the program’s eligibility criteria.

Cesamet (nabilone)

Drug company: Meda Pharmaceuticals
800-526-3840

Cesamet is used for the treatment of patients with nausea and vomiting associated with cancer chemotherapy.

(Meda Pharmaceuticals does not currently offer any financial assistance program for Cesamet.)

Emend (aprepitant)

Drug company: Merck
855-257-3932

Emend is a substance P/neurokinin-1 receptor antagonist used to prevent nausea and vomiting associated with chemotherapy in pediatric and adult patients with cancer. Emend is also used to prevent postoperative nausea and vomiting in adults.

The Merck Access Program offers 1 financial assistance program for patients using Emend:

Merck Patient Assistance Program

Patients without insurance or prescription coverage may be eligible to receive Emend free. Eligible patients must have an annual household income of $48,240 or less for individuals, $64,960 or less for couples, or $98,400 or less for a family of 4. Patients with insurance, including Medicare Part D, who still have difficulty paying for medicines may request that an exception be made, provided their annual household income is not more than a set limit.

Marinol (dronabinol)

Drug company: AbbVie
800-222-6885

Marinol is used for the treatment of patients with nausea and vomiting associated with cancer chemotherapy.

(AbbVie does not currently offer any financial assistance programs for Marinol.)

Sancuso (granisetron transdermal system)

Drug company: Kyowa Kirin
800-676-5884

Sancuso is a serotonin-3 receptor antagonist used to prevent nausea and vomiting in patients receiving chemotherapy for up to 5 consecutive days.

Kyowa Kirin offers 2 financial assistance programs for patients using Sancuso:

Sancuso Copay Assistance Card Program

Insured patients can use the Sancuso Copay Assistance Card for up to 48 patches per patient, with a maximum of 4 patches and $1,200 benefit monthly. With the card, patients will pay the initial $20 of their copay and any remaining out-of-pocket costs will be reduced by up to $300 monthly.

Sancuso Patient Assistance Program

Patients who do not have insurance and who do have an income at or below 300% of the current federal poverty level are eligible to receive free Sancuso.

Sustol (granisetron)

Drug company: Heron Therapeutics
855-787-8656

Sustol is a serotonin-3 receptor antagonist used, in combination with antiemetic agents, to prevent acute and delayed nausea and vomiting associated with chemotherapy.

Sustol Connect Patient Services offers 2 financial assistance programs for patients using Sustol:

Sustol Copay Assistance Program

Privately insured and uninsured patients can benefit from this copay program. Patients with private insurance will pay $0 copay per dose for a 12-month calendar period for Sustol. For uninsured patients, the program will cover $150 per prescription up to $1,800 per calendar year. Patients must reapply after each 12-month period.

Sustol Patient Assistance Program

Sustol can be provided at no cost to patients with financial hardship who meet the program eligibility criteria.

Varubi (rolapitant)

Drug company: Tesaro
844-283-7276

Varubi is a substance P/neurokinin-1 receptor antagonist used, in combination with other antiemetic agents, to prevent delayed nausea and vomiting associated with chemotherapy.

Tesaro offers 3 financial assistance programs for patients using Varubi:

First Dose Program

Once enrolled in the TOGETHER with TESARO First Dose Program, patients may qualify for a single-dose wallet card of Varubi at no cost in the event of an insurance coverage delay. Patients can only be enrolled in the program through their healthcare provider.

Commercial Co-pay Assistance Program

Patients with private insurance can use this virtual card to reduce their copay and/or coinsurance for Varubi to $0, with a $300 annual maximum benefit. The patient’s healthcare provider must complete and submit the enrollment form.

Tesaro Patient Assistance Program

Patients who are uninsured or underinsured and meet certain financial eligibility criteria may qualify to receive Varubi for free. Patients can only be enrolled in the program through their healthcare provider.

Cytokine Release Syndrome

Actemra (tocilizumab)

Drug company: Genentech
866-422-2377

Actemra is an interleukin-6 receptor antagonist used for the treatment of adults and pediatric patients age 2 or older who have CAR T-cell–induced, severe or life-threatening cytokine release syndrome.

Genentech offers 2 financial assistance programs for patients using Actemra:

Actemra Co-pay Card Program

This program helps eligible, privately insured patients, who have been prescribed Actemra for any approved indication, to pay just $5 per drug copay. The card is valid for up to $15,000 in assistance within a 12-month period.

Genentech Access to Care Foundation

The foundation provides Actemra free of charge to uninsured and underinsured patients whose household income is less than $100,000. Actemra is also provided free of charge for patients whose household income is less than $150,000 and whose out-of-pocket prescription costs exceed 5% of their income (regardless of insurance).

Neutropenia/Febrile Neutropenia

Neulasta (pegfilgrastim)

Drug company: Amgen
888-427-7478

Neulasta is a leukocyte growth factor used to decrease the incidence of infection associated with febrile neutropenia.

Amgen offers 2 financial assistance programs for patients using Neulasta:

Neulasta FIRST STEP Program

For privately insured patients whose insurance covers Neulasta, this program ensures a copay of $0 for the first dose, and $25 for each dose thereafter, with a maximum benefit of $10,000 per patient per calendar year.

Amgen Safety Net Foundation

Patients with limited or no drug coverage, and patients with Medicare Part D who satisfy the income eligibility requirements, can receive Neulasta for free through this nonprofit program from Amgen.

Neupogen (filgrastim)

Drug company: Amgen
888-427-7478

Neupogen is a leukocyte growth factor used to decrease infections associated with febrile neutropenia. Neupogen is also used for the treatment of patients with neutropenia.

Amgen offers 2 financial assistance programs for patients using Neupogen:

Neupogen FIRST STEP Program

For privately insured patients whose insurance covers Neupogen, this program ensures a copay of $0 for the first dose, and $25 for each dose thereafter, with a maximum benefit of $10,000 per patient per calendar year.

Amgen Safety Net Foundation

Patients with limited or no drug coverage, and patients with Medicare Part D who satisfy the income eligibility requirements, can receive Neupogen for free through this nonprofit program from Amgen.

Zarxio (filgrastim-sndz)

Drug company: Sandoz
844-726-3691

Zarxio is a leukocyte growth factor used to decrease the incidence of infection associated with febrile neutropenia. Zarxio is also used for the treatment of patients with neutropenia.

Sandoz One Source offers 1 financial assistance program for patients using Zarxio:

Sandoz One Source Commercial Co-Pay Program

Through this program, privately insured patients will pay $0 for the first dose of Zarxio and $10 for subsequent doses with a maximum benefit of $10,000 annually. There is no income eligibility requirement.

Oral and Gastrointestinal Mucosal Injury

Gelclair (glycyrrhetinic acid/povidone/sodium hyaluronate)

Drug company: Helsinn
855-327-2246

Gelclair is a bioadherent oral rinse gel used for the management of pain and relief of pain of patients with oral mucositis or stomatitis.

Helsinn offers 1 financial assistance program for patients using Gelclair:

Gelclair Rx Program

A simple one-stop solution for patients with oral mucositis or stomatitis, this program allows patients to receive Gelcair bioadherent oral rinse gel within 24 hours of prescription receipt or confirmation. Most insured patients pay $0 out of pocket.

SalivaMAX (an oral rinse)

Drug company: Forward Science
855-696-7254

SalivaMAX is a supersaturated calcium phosphate rinse used for the treatment of patients with mucositis and dryness of the oral mucosa caused by radiation or high-dose chemotherapy.

Forward Science offers 1 financial assistance program for patients using SalivaMAX:

Forward Science Patient Assistance Program

This program benefits patients who are privately insured or uninsured. For patients with insurance coverage and a copay, Forward Science pays the copay amount, resulting in no out-of-pocket costs for the patient. For patients without insurance coverage, the program offers a discounted cash price.

Table. Drugs Prescribed for Side-Effects Management (Supportive Care)

Anemia
  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services
    Drug name (generic name)
  • Aranesp (darbepoetin alfa)
  • Drug company
  • Amgen
  • Indication
  • Anemia
  • Patient support services
  • Amgen Safety Net Foundation
    888-762-6436

    Drug name (generic name)
  • Epogen (epoetin alfa)
  • Drug company
  • Amgen
  • Indication
  • Anemia
  • Patient support services
  • (No specific program)
    888-427-7478


Bone Metastases/Reduced Bone Mass
  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services
    Drug name (generic name)
  • Prolia (denosumab) Injection
  • Drug company
  • Amgen
  • Indication
  • To increase bone mass in high-risk men receiving androgen-deprivation therapy for nonmetastatic prostate cancer, and in women receiving adjuvant aromatase inhibitor therapy for breast cancer
  • Patient support services
  • Prolia Copay Program
    844-369-9962

    Prolia FIRST STEP Program
    888-657-8371

    Amgen Safety Net Foundation
    888-762-6436


Cancer Pain
  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services
    Drug name (generic name)
  • Actiq (fentanyl citrate)
  • Drug company
  • Teva
  • Indication
  • Breakthrough cancer pain
  • Patient support services
  • (No specific program)
    888-587-3263


    Drug name (generic name)
  • Lazanda (fentanyl)
  • Drug company
  • Depomed
  • Indication
  • Breakthrough cancer pain
  • Patient support services
  • Lazanda Savings Card
    877-546-5779

    Drug name (generic name)
  • Subsys (fentanyl sublingual spray)
  • Drug company
  • Insys
  • Indication
  • Breakthrough cancer pain
  • Patient support services
  • Subsys Copay Savings Program
    855-766-6502

Chemotherapy-Induced Nausea and Vomiting
  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services

    Drug name (generic name)
  • Aloxi (palonosetron hydrochloride)
  • Drug company
  • Eisai/Helsinn
  • Indication
  • Chemotherapy-induced nausea and vomiting
  • Patient support services
  • Aloxi Patient Assistance Program
    866-613-4724

    Drug name (generic name)
  • Cesamet (nabilone)
  • Drug company
  • Meda Pharmaceuticals
  • Indication
  • Chemotherapy-induced nausea and vomiting
  • Patient support services
  • (No specific program)
    800-526-3840

    Drug name (generic name)
  • Emend (aprepitant)
  • Drug company
  • Merck
  • Indication
  • Chemotherapy-induced nausea and vomiting

    Postoperative nausea and vomiting
  • Patient support services
  • Merck Patient Assistance Program
    855-257-3932

    Drug name (generic name)
  • Marinol (dronabinol)
  • Drug company
  • AbbVie
  • Indication
  • Chemotherapy-induced nausea and vomiting
  • Patient support services
  • (No specific program)
    800-222-6885




Cytokine Release Syndrome
  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services

Neutropenia/Febrile Neutropenia
  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services



Oral and Gastrointestinal Mucosal Injury
  • Drug name (generic name)
  • Drug company
  • Indication
  • Patient support services
    Drug name (generic name)
  • Gelclair (glycyrrhetinic acid/povidone/sodium hyaluronate)
  • Drug company
  • Helsinn
  • Indication
  • Oral mucositis

    Stomatitis
  • Patient support services
  • Gelclair Rx Program
    855-327-2246


Recommended For You
ImmunotherapySide-Effects Management
Considering the Side Effects Associated with Immunotherapies
By Dana Taylor
Patients who are receiving immunotherapy should consult with their doctor immediately if and when any side effects occur, because immune-related adverse events may occur during therapy or even after discontinuation of therapy.
Side-Effects ManagementSurvivorship
Why Didn’t You Mention the Long-Term Side Effects of Cancer Treatment?
By Dan Dean
The long-term side effects of treatment can be an overlooked part of cancer care. "We're learning as they're surviving, and we can't assume we know everything," says Pam Simon, MSN.
Breast CancerChemotherapySide-Effects Management
The Aftershocks Kept Coming: What to Expect After Cancer Treatment
By Lisa A. D'Ottavio
Breast cancer survivor Lisa D’Ottavio describes the side effects of treatment that she experienced, from chemo hair loss, neuropathy, and lymphedema, to radiation effects and more.
Breast CancerSide-Effects Management
Managing Lymphedema Associated with Breast Cancer
By Nancy Litterman Howe, MS, CES
Andrea Brennan, a certified lymphedema therapist, sheds light on the challenges faced with lymphedema associated with breast cancer and debunks several myths about the disease.
Last modified: April 16, 2018

Subscribe to CONQUER: the patient voice® magazine

Receive timely cancer news & updates, patient stories, and more.

Country